Search - tctmd.com

Displaying 281 - 300 of 653

Sort: Relevancy | Date

News Daily News

Platelet Reactivity High in Most Patients Who Develop Stent Thrombosis

L.A. McKeown

December 20, 2017

News Daily News

Radial Access Best for PCI Following Thrombolysis in STEMI

Michael O'Riordan

November 27, 2017

News Conference News AHA 2017

RE-DUAL PCI Findings Consistent Across Key Subgroups

Todd Neale

November 16, 2017

News Conference News AHA 2017

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

Michael O'Riordan

November 15, 2017

News Conference News AHA 2017

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

Yael L. Maxwell

November 14, 2017

News Conference News AHA 2017

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

Yael L. Maxwell

November 12, 2017

Presentation TCT 2017

TCT 75: Impact of the Timing of P2Y12 Inhibitor Discontinuation Prior to CABG in Patients With Left Main Disease: Results from the EXCEL Trial

Presenter: Adrian P. Banning, John D. Puskas, Christopher Kelly, MD

October 31, 2017

Presentation TCT 2017

Rationale and Studies of P2Y12 Inhibitor Monotherapy

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Roxana Mehran

October 30, 2017

Presentation TCT 2017

Switching Between Oral P2Y12 Receptor Inhibitors: When and How?

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Matthew J. Price

October 30, 2017

Presentation TCT 2017

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Fabiana Rollini

October 30, 2017

Presentation TCT 2017

Debate: Making the Case for Not Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Presenter: John A. Bittl, Freek W.A. Verheugt, Somjot S. Brar

October 30, 2017

Presentation TCT 2017

Debate: Making the Case for Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Presenter: John A. Bittl, Freek W.A. Verheugt, Dimitrios Alexopoulos

October 30, 2017

Presentation TCT 2017

Treatment of Coronary Bifurcations in the Contemporary Era of P2Y12 Inhibitors and "Biologically Active Stents"

Presenter: Davide Capodanno, David Hildick-Smith, Marco Zimarino

October 30, 2017

News Conference News TCT 2017

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Todd Neale

October 30, 2017

News Daily News

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

Michael O'Riordan

October 11, 2017

News Daily News

Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI

Yael L. Maxwell

October 03, 2017

News Daily News

Acute MI Patients With Cancer History Less Likely to Get Evidence-Based Therapies

L.A. McKeown

September 25, 2017

News Daily News

New Performance and Quality Metrics for STEMI and NSTEMI Care

Michael O'Riordan

September 21, 2017

News Daily News

Extended Low-Dose Ticagrelor May Prevent Adverse Events Post-MI, Study Finds

Yael L. Maxwell

September 12, 2017

News Conference News ESC 2017

DAPT Can Be Safely De-Escalated Post-PCI Based on Platelet Function Testing

Todd Neale

September 07, 2017

Advertisement

Platelet Reactivity High in Most Patients Who Develop Stent Thrombosis

Radial Access Best for PCI Following Thrombolysis in STEMI

RE-DUAL PCI Findings Consistent Across Key Subgroups

‘De-escalating’ P2Y12 Inhibition Possible in Acute MI Patients: PRAGUE-18

GEMINI-ACS-1 Substudy: P2Y12 Inhibitor Switching Is Uncommon After ACS

DACAB: Ticagrelor and Aspirin Improve SVG Patency at 1 Year Post-CABG vs Monotherapy

TCT 75: Impact of the Timing of P2Y12 Inhibitor Discontinuation Prior to CABG in Patients With Left Main Disease: Results from the EXCEL Trial

Rationale and Studies of P2Y12 Inhibitor Monotherapy

Switching Between Oral P2Y12 Receptor Inhibitors: When and How?

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Debate: Making the Case for Not Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Debate: Making the Case for Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Treatment of Coronary Bifurcations in the Contemporary Era of P2Y12 Inhibitors and "Biologically Active Stents"

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Bioresorbable Scaffolds Not to Be Chosen Over DES, Says European Task Force

Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI

Acute MI Patients With Cancer History Less Likely to Get Evidence-Based Therapies

New Performance and Quality Metrics for STEMI and NSTEMI Care

Extended Low-Dose Ticagrelor May Prevent Adverse Events Post-MI, Study Finds

DAPT Can Be Safely De-Escalated Post-PCI Based on Platelet Function Testing

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content